Literature DB >> 2010561

Amikacin pharmacokinetics: wide interpatient variation in 98 patients.

D E Zaske1, R G Strate, P R Kohls.   

Abstract

The disposition of amikacin was studied in 98 patients receiving treatment for severe gram-negative sepsis. Several factors were identified which were significantly related to the drug's elimination rate. These included renal function (r = .67), age (r = -.55), distribution volume (r = .34), and weight (r = -.31). These variables explain 62% of the variance (R2) in elimination rate constant when combined in a multiple regression model. The drug's half-life demonstrated considerable interpatient variation in patients with a normal serum creatinine (.68-14.4 hrs) or with a normal creatinine clearance (.68-7.2 hrs). The drug's distribution volume ranged from .08 to .48 L/Kg. The drug's clearance varied from 6.5 to 200 mL/hr/kg for patients with a normal serum creatinine and 17.8 to 200 mL/hr/kg for patients with a normal creatinine clearance. The interpatient variation in the drug's kinetic parameters is a concerning clinical problem. Measuring serum amikacin concentrations and adjusting dosage regimens are necessary to achieve desired peak and trough serum concentrations.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2010561     DOI: 10.1002/j.1552-4604.1991.tb03700.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

1.  Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis.

Authors:  Catherine M T Sherwin; Sofia Svahn; Antje Van der Linden; Roland S Broadbent; Natalie J Medlicott; David M Reith
Journal:  Eur J Clin Pharmacol       Date:  2009-03-21       Impact factor: 2.953

Review 2.  Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies.

Authors:  Amélie Marsot; Romain Guilhaumou; Camille Riff; Olivier Blin
Journal:  Clin Pharmacokinet       Date:  2017-02       Impact factor: 6.447

3.  Influence of clinical diagnosis in the population pharmacokinetics of amikacin in intensive care unit patients.

Authors:  S Romano; M Del Mar Fdez de Gatta; V Calvo; E Mendez; A Domínguez-Gil; J M Lanao
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

4.  Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions.

Authors:  Norma A Aréchiga-Alvarado; Susanna E Medellín-Garibay; Rosa Del C Milán-Segovia; Arturo Ortiz-Álvarez; Martín Magaña-Aquino; Silvia Romano-Moreno
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

5.  Optimized Extraction of Amikacin from Murine Whole Blood.

Authors:  Roccaldo Sardella; Styliani Xiroudaki; Laura Mercolini; Samuele Sabbatini; Claudia Monari; Stefano Perito; Federica Ianni; Anna Vecchiarelli; Stefano Giovagnoli
Journal:  Molecules       Date:  2021-01-27       Impact factor: 4.411

Review 6.  Amikacin Therapy in Japanese Pediatric Patients: Narrative Review.

Authors:  Hideo Kato; Yukihiro Hamada
Journal:  Int J Environ Res Public Health       Date:  2022-02-10       Impact factor: 3.390

7.  Amikacin population pharmacokinetics in critically ill Kuwaiti patients.

Authors:  Kamal M Matar; Yousef Al-lanqawi; Kefaya Abdul-Malek; Roger Jelliffe
Journal:  Biomed Res Int       Date:  2013-01-30       Impact factor: 3.411

8.  An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration.

Authors:  Deirdre M D'Arcy; Eoin Casey; Caitriona M Gowing; Maria B Donnelly; Owen I Corrigan
Journal:  BMC Pharmacol Toxicol       Date:  2012-11-08       Impact factor: 2.483

9.  Population Pharmacokinetic Analysis of Amikacin for Optimal Pharmacotherapy in Korean Patients with Nontuberculous Mycobacterial Pulmonary Disease.

Authors:  Xuanyou Jin; Jaeseong Oh; Joo-Youn Cho; SeungHwan Lee; Su-Jin Rhee
Journal:  Antibiotics (Basel)       Date:  2020-11-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.